Company Overview and News

 
Aurobindo Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AUROPHARMA 524804 ARBQY

 
Aurobindo Pharma gets nod from South African health authority for HIV drug

2018-09-18 moneycontrol
Aurobindo Pharma Tuesday said it has received approval from the South African health authority to market its Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (DLT) tablets, the first-line regimen for HIV patients as per latest WHO guidelines.
AUROPHARMA 524804 ARBQY

 
Aurobindo Pharma shares gain over 1% on SAHPRA approval for HIV drug

2018-09-18 moneycontrol
Aurobindo Pharma share price gained more than a percent in morning on Tuesday on receiving approval from South African health regulator for latest fixed dose triple combination tablets.
AUROPHARMA 524804 ARBQY

 
Aurobindo Pharma Limited - Press Release

2018-09-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AUROPHARMA 524804 ARBQY

 
D-Street Buzz: IT stocks gain led by Oracle Financial; sugar stocks continue to rally, RIL drags

2018-09-17 moneycontrol
The Indian stock market have extended the morning loses and are trading well in the red this Monday afternoon with the Nifty50 down 102 points and is trading at 11,412 while the Sensex is trading lower by 391 points at 37,699.
GRASIM IOC 500408 SUZLON 500325 BRTQY TCHQY 532755 SONATSOFTW 532480 500696 BJJQY BRITANNIA SUEL RLNIY 504212 SBAZ GRSJY 524804 UNITDSPR ALBK YYBKY 530965 532667 TECHM 532432 BAJFINANCE TATASTEEL TATLY UQNTY 500300 500825 AUROPHARMA 533271 GODREJIND RELIANCE 512573 HINDUNILVR ASHOKA 532221 500470 RIGD SAKHTISUG UNIVCABLES 500034 YESBANK UBNC AVANTI 532648 GRSXY TTST ARBQY TATAELXSI 507315 500164

 
Aurobindo Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AUROPHARMA 524804 ARBQY

1
Broker's call: Aurobindo Pharma (Buy)

2018-09-11 thehindubusinessline
Aurobindo Pharma is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).
AUROPHARMA 524804 ARBQY NVS

 
Actavis to Sandoz, Aurobindo Pharma is scaling up biz one acquisition at a time

2018-09-11 moneycontrol
India’s second-largest drug maker by sales Aurobindo Pharma last week acquired Sandoz’s dermatology business and a portfolio of oral solid products along with commercial and manufacturing infrastructure in the US for $900 million, making it the largest outbound deal by an Indian pharma company.
AUROPHARMA 524804 ARBQY

 
Pharma weekly wrap: A busy week with Aurobindo#39;s US buyout and break-up of Singh brothers

2018-09-08 moneycontrol
The biggest development of the week was India’s second-largest drugmaker Aurobindo Pharma's acquisition of commercial operations and three manufacturing units from Sandoz, a Novartis generic division, in the United States.
FORTIS AUROPHARMA 524804 ARBQY 532915 RELIGARE 532843

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 05156Y106